Study of Apatinib in Metastatic Triple-Negative Breast Cancer Patients
Status:
Completed
Trial end date:
2014-09-01
Target enrollment:
Participant gender:
Summary
The hypothesis of this clinical research study is to discover if the study drug apatinib can
shrink or slow the growth of pretreated metastatic triple-negative breast cancer.